Panacea Biotech Company to make Sputnik-V vaccine in the country, DCGI approved

The Drug Controller General of India has approved New Delhi-based biotechnology company Panacea Biotech to develop Russian vaccine Sputnik-V in India. The company said that we will be the first firm to make this vaccine locally. Panacea Biotech is one of six companies that have partnered with Russia’s Sovereign Wealth Fund, the Direct Investment Fund of Russia, to market the vaccine globally. Biotechnology company Panacea Biotech said in a statement that Panacea Biotech is in the process of obtaining a manufacturing license from the Drug Controller General of India for the Sputnik-V vaccine against the corona epidemic in collaboration with the Russian Direct Investment Fund. A license is a prerequisite for using Sputnik-V manufactured by Panacea Biotech in India.
This two-dose vaccine is 91.6 percent effective against the corona epidemic. The first consignment of the Sputnik-V vaccine, prepared by Panacea Biotech, was sent to the Gamalaya center in Russia, where it underwent a fluid control check. At the same time, the company said that the first consignment made at Baddi has successfully passed all the checks of liquidity control at Gamaliya Center in Russia and Central Drug Laboratory, Kasauli in India.

Even though the company did not respond to further questions about when the vaccine will be available. People familiar with the matter said on condition of anonymity that under its terms with RDIF, Panacea is likely to produce 100 million doses each year.